MIR602 overexpression has been associated with a poor prognosis in oesophageal squamous cell carcinoma and in glioblastoma multiforme [68,73] and a favourable outcome in pancreatic ductal adenocarcinoma [74]. Here, MIR602 is linked to glioblastoma.